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Chlamydialike
Organisms and
Atherosclerosis
To the Editor: Chlamydophila
pneumoniae  causes pneumonia, but
its role in the pathogenesis of athero-
sclerosis is controversial (1–4). The
role of C. pneumoniae in atheroscle-
rosis is supported by seroepidemio-
logic studies and detection in athero-
sclerotic lesions by polymerase chain
reaction (PCR), immunohistologic
analysis, culture, and electron micro-
scopy (2,3). However, these results
were not confirmed by other serologic
or PCR-based studies (4). Meijer et al.
evaluated abdominal aortic aneurysm
biopsy specimens and detected C.
pneumoniae membrane antigen more
frequently than lipopolysaccharide
antigens but did not detect heat shock
protein 60 (1). In addition, they could
not amplify or detect specific C. pneu-
moniae  DNA by PCR and fluores-
cence in situ hybridization (1). They
hypothesized that this discrepancy
may result from a chlamydialike
organism present in aortic samples
that has surface antigens similar to
those of C. pneumoniae. 
Parachlamydia acanthamoebae
and  Neochlamydia hartmanellae are
chlamydialike organisms that share
≈86% 16S rRNA sequence similarity
with  C.  pneumoniae  (5). Like C.
pneumoniae,  they have elementary
and reticulate bodies visible by elec-
tron microscopy (6).  Neochlamydia-
related DNA (GenBank accession no.
AF097191) has been amplified from 5
different arterial samples, including 1
aortic aneurysm (7), and a relation-
ship (p = 0.009) between cerebral
hemorrhage and serologic evidence of
Parachlamydia  infection has been
reported (8). Therefore, we investigat-
ed the role of Parachlamydia  in
pathogenesis of atherosclerosis by
using a molecular approach.
We analyzed 78 surgical samples
from 27 patients undergoing aortic or
carotid surgery for atherosclerotic dis-
ease at Hôpital Nord in Marseille
from June 1, 2003, to December 31,
2003. The study was approved by the
local ethics committee, and written
informed consent was obtained from
all participants. Demographic and
clinical data were prospectively
recorded. 
DNA was extracted from aortic or
carotid samples with atherosclerotic
lesions by using the QIAamp DNA
tissue kit (Qiagen, Courtaboeuf,
France), according to the manufactur-
er’s instructions. A nested PCR was
performed by using external primers
16SIGF (5′-CGGCGTGGATGAG-
GCAT-3′) and 16SIGR (5′-TCAGTC-
CCAGTGTTGGC-3′) (9) and internal
primers CHL16SFOR2 (5′-CGTG-
GATGAGGCATGCAAGTCGA-3′)
and CHL16SREV2 (5′-CAATCTCT-
CAATCCGCCTAGACGTCTTAG-
3′) (7). PCR included negative con-
trols from the DNA extraction step.
DNA extractions and PCR amplifica-
tions were conducted in a laboratory
in which parachlamydial DNA had
not been extracted or amplified. PCR
products were purified by using the
QIAquick PCR purification kit
(Qiagen) and sequenced by using the
d-rhodamine terminator cycle
sequencing reaction kit (Perkin-Elmer
Biosystems, Warrington, UK) and a
3100 ABI Prism automated sequencer
(Applied Biosystems, Courtaboeuf,
France). 
Sequences were analyzed with
BLAST (http://www.ncbi.nlm.nih.
gov/BLAST/) using gap existence and
extension penalties of 5 and 2, respec-
tively. Results were considered posi-
tive only when the sequence of the
amplified product exhibited a best
BLAST hit with a chlamydialike
organism. Statistical analyses were
performed with STATA software
(Stata Corporation, College Station,
TX, USA).
A positive PCR result was
obtained with samples from 5 (18.5%)
of 27 patients (Table). Three
sequences had a best BLAST hit with
the sequence of Parachlamydia  sp.
UV7 (GenBank accession no.
AJ715410), with a sequence similari-
ty ranging from 99% to 100%. The
other 2 sequences had 98% sequence
similarity with Neochlamydia-related
symbiont TUME-1 (GenBank acces-
sion no. AF098330). PCR positivity
was not associated with age, sex, or
location of the atherosclerotic lesion. 
All patients with positive PCR
results were >68 years of age. Patients
without cardiovascular risk factors
were more likely than those with
>1 risk factor to have positive PCR
results (p = 0.023). Despite the small
number of patients in this study, this
association was also confirmed in a
multivariate logistic regression model
adjusted for sex and previous cardio-
vascular disease (odds ratio 0.035,
95% confidence interval 0.001–0.94). 
These findings suggest that
Parachlamydia  and  Neochlamydia
are associated with atherosclerosis. In
addition, these obligate intracellularLETTERS
bacteria may be present in both
carotid and aortic atherosclerotic
lesions of elderly patients. 
Chlamydialike organisms in ather-
osclerotic lesions may explain contro-
versies about the role of C. pneumoni-
ae in pathogenesis of atherosclerosis
(4). Some PCRs might amplify both
Chlamydia and chlamydialike organ-
isms, leading to erroneous conclu-
sions, especially when the specificity
of the product is not confirmed by
sequencing. Chlamydialike organisms
in atherosclerotic lesions might also
explain discrepancies of serologic
studies (4). Parachlamydiaceae likely
cross-react with C.  pneumoniae  (1).
Such cross-reactivity will not be rec-
ognized if patients with positive sero-
logic results for C. pneumoniae  are
not tested for antibodies to chlamydi-
alike organisms. This cross-reactivity
may result in false-positive serologic
results for C. pneumoniae, especially
when low antibody titers (8–16) are
considered positive. 
Since elementary and reticulate
bodies are similar in both Chlamydia-
ceae and  Parachlamydiaceae (6),
Chlamydiales cannot be identified in
a specimen solely by electron
microscopy. Consequently, elemen-
tary and reticulate bodies in athero-
sclerotic lesions (10) might be
chlamydialike organisms and not C.
pneumoniae. If chlamydialike organ-
isms are involved in the pathogenesis
of atherosclerosis, this finding would
have public health implications, given
their presence in free-living amebae
that are widespread in water. 
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